The initial publication that demonstrated the association of the low-level promoter methylation of BRCA1 in blood with the development of BRCA1-like breast cancer (with tumor displaying features typical for cancer with mutated BRCA1 gene)3, targeted the region in which methylation changes had previously been associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens17. This evidence concerns the gene BRCA1 and breast carcinoma.